TRACON Pharmaceuticals (TCON) Files $57.5M IPO

TRACON Pharmaceuticals (NASDAQ: TCON) filed with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $57.5 million. The ticker "TCON" was proposed and the company plans to list on the NASDAQ.

Wells Fargo and Stifel are the lead book-running managers of the offering. Needham & Company and Oppenheimer & Co are co-managers.

TRACON Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, or AMD, and fibrotic diseases. They are a leader in the field of endoglin biology and are using our expertise to develop antibodies that bind to the endoglin receptor. Endoglin is essential to angiogenesis, the process of new blood vessel formation, and a key contributor to the development of fibrosis, or tissue scarring. Lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor, or VEGF, pathway. Other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In March 2014, Santen Pharmaceutical Co., Ltd., or Santen, a global ophthalmology company, licensed from the company exclusive worldwide rights to develop and commercialize our anti-endoglin antibodies for ophthalmology indications, including AMD. They retain global rights to develop and commercialize our anti-endoglin antibodies outside of the field of ophthalmology, as well as global rights to TRC102 in all indications.

You May Also Be Interested In